Title: Increased Glypican-3 immunostaining is associated with longer survival outcomes in colorectal carcinoma
Abstract: ENWEndNote BIBJabRef, Mendeley RISPapers, Reference Manager, RefWorks, Zotero AMA Al-Maghrabi J, Al-Mansouri Z, Al-Harbi A, Assidi M, Buhmeida A, Gomaa W. Increased Glypican-3 immunostaining is associated with longer survival outcomes in colorectal carcinoma. Polish Journal of Pathology. 2022;73(1):14-20. doi:10.5114/pjp.2022.117172. APA Al-Maghrabi, J., Al-Mansouri, Z., Al-Harbi, A., Assidi, M., Buhmeida, A., & Gomaa, W. (2022). Increased Glypican-3 immunostaining is associated with longer survival outcomes in colorectal carcinoma. Polish Journal of Pathology, 73(1), 14-20. https://doi.org/10.5114/pjp.2022.117172 Chicago Al-Maghrabi, Jaudah, Zuhoor Al-Mansouri, Abdullah Al-Harbi, Mourad Assidi, Abdelbaset Buhmeida, and Wafaey Gomaa. 2022. "Increased Glypican-3 immunostaining is associated with longer survival outcomes in colorectal carcinoma". Polish Journal of Pathology 73 (1): 14-20. doi:10.5114/pjp.2022.117172. Harvard Al-Maghrabi, J., Al-Mansouri, Z., Al-Harbi, A., Assidi, M., Buhmeida, A., and Gomaa, W. (2022). Increased Glypican-3 immunostaining is associated with longer survival outcomes in colorectal carcinoma. Polish Journal of Pathology, 73(1), pp.14-20. https://doi.org/10.5114/pjp.2022.117172 MLA Al-Maghrabi, Jaudah et al. "Increased Glypican-3 immunostaining is associated with longer survival outcomes in colorectal carcinoma." Polish Journal of Pathology, vol. 73, no. 1, 2022, pp. 14-20. doi:10.5114/pjp.2022.117172. Vancouver Al-Maghrabi J, Al-Mansouri Z, Al-Harbi A, Assidi M, Buhmeida A, Gomaa W. Increased Glypican-3 immunostaining is associated with longer survival outcomes in colorectal carcinoma. Polish Journal of Pathology. 2022;73(1):14-20. doi:10.5114/pjp.2022.117172.